Trevena Inc (TRVN) Wednesday reported fourth-quarter losses that were wider than analysts’ estimates, sending its shares down 5.4% during pre-market trading. Helped by substantially lower research and development expenses during the quarter, net loss narrowed to 10 cents per share from 24 cents per share a year ago.
However, this wasn’t good enough for the street, which was expecting a loss of only 6 cents per share.
Q4 revenue of the clinical-stage biopharmaceutical company stood at $232 million, surpassing analysts’ estimate.
TRVN shares have slipped 23% in the trailing 52 weeks. Meanwhile, it has gained 16% since the beginning of this year.
Trevena announced that it has identified a new candidate for its S1P receptor program, designated as TRV045, which holds promise as a new mechanism for non-opioid treatment of chronic pain and other central nervous system disorders.
CEO Carrie Bourdow said, “We have achieved meaningful milestones with our early-stage pipeline assets and, in 2019, expect to continue the development of these assets to build long-term stockholder value.”
On Tuesday, shares of Cara Therapeutics (CARA) surged about 10% during the extended trading hours, after reporting better-than-expected results in the fourth quarter. Viking Therapeutics (VKTX) is scheduled to report quarterly results after the closing bell today.
Energy giant ExxonMobil Corporation (NYSE: XOM) reported a profit for the second quarter of 2021, compared to a loss last year, even as operating conditions continued to improve. The results
Caterpillar Inc (NYSE: CAT) reported second-quarter 2021 financial results before the regular market hours on Friday. The manufacturer of construction machinery and equipment reported Q2 revenue of $12.9 billion, up
Chevron Corporation (NYSE: CVX) reported second-quarter 2021 earnings results today. Total revenues amounted to $37.5 billion compared to $13.4 billion in the year-ago period. The reported net income was $3.1